Supplementary Table S1: Search Strategy

Database	Query	Search details	Results
PubMed	CETP inhibitors OR anacetrapib OR evacetrapib OR dalcetrapib) AND Cardiovascular Outcomes	{("CETP"[All Fields] AND ("antagonists and inhibitors"[MeSH Subheading] OR ("antagonists"[All Fields] AND "inhibitors"[All Fields]) OR "antagonists and inhibitors"[All Fields] OR "inhibitors"[All Fields]} OR {("anacetrapib"[Supplementary Concept] OR "anacetrapib"[All Fields]) OR {"evacetrapib"[Supplementary Concept] OR "evacetrapib"[All Fields]) OR ("dalcetrapib"[Supplementary Concept] OR "dalcetrapib"[All Fields]) AND (("cardiovascular system"[MeSH Terms]) OR ("cardiovascular"[All Fields] AND "system"[All Fields]} OR "cardiovascular system"[All Fields] OR "cardiovascular"[All Fields] OR ("cardiovasculars"[All Fields]) AND ("outcome"[All Fields]) OR "outcomes"[All Fields])}	248
Embase	obicetrapib OR evacetrapib OR dalcetrapib OR anacetrapib OR cholesteryl ester transfer protein Inhibitor		245
Cochrane Library	obicetrapib OR evacetrapib OR dalcetrapib OR anacetrapib OR cholesteryl ester transfer protein Inhibitor		176
Medline	obicetrapib OR evacetrapib OR dalcetrapib OR anacetrapib OR cholesteryl ester transfer protein Inhibitor		312



Supplementary Figure S1: Quality assessment of the independent researcher XY. The majority of the studies were deemed to have a low risk of bias, but five of them were flagged for exhibiting a high risk of bias. This was primarily attributed to issues concerning how the outcome was measured and which outcomes were selected for reporting. Accelerate AM et al., 2017 [1]; Ballantyne* et al., 2017 Am J Cardiol Vol. 120 [2]; Ballantyne et al., 2017 [3]; DAL outcome et al., 2012 [4]; Dal plaque ZA et al., 2011 [5]; Dal vessel et al., 2012 [6]; DEFINE CP et al., 2010 [7]; E. Sammons et al., 2022 [8]; Menon et al., 2020 [9]; REALIZE JJ et al., 2015 [10]; REVEAL et al., 2017 [11]; Stein et al., 2010 [12]; Teramoto et al., 2017 [13];



Supplementary Figure S2: Funnel Plot. An asymmetrical distribution of data points was noted in the funnel chart, indicating the possibility of publication bias within the studies. This pattern may also indicate a potential bias associated with smaller studies. Significance was determined by a p-value < 0.05, indicating statistical significance.

SUPPLEMENTARY FOREST PLOTS



Supplementary Figure S3. Forest Plot of the Outcome of Stroke

Ballantyne* et al., 2017 Am J Cardiol Vol. 120 [2]; DEFINE CP et al., 2010 [7]; E. Sammons et al., 2022 [8]; REALIZE JJ et al., 2015 [10]; Teramoto et al., 2017 [13]; DAL outcome et al., 2012 [4]; Dal vessel et al., 2012 [6]; Stein et al., 2010 [12]; Accelerate AM et al., 2017 [1]. The values of each study (represented by black diamonds), in which the size is determined by 95% CI; the effect size of each individual study in the meta-analysis (represented by blue squares).



Supplementary Figure S4. Forest Plot of the Outcome of Hospitalization due to Acute Coronary Syndrome

Ballantyne* et al., 2017 Am J Cardiol Vol. 120 [2]; DEFINE CP et al., 2010 [7]; E. Sammons et al., 2022 [8]; REALIZE JJ et al., 2015 [10]; Teramoto et al., 2017 [13]; DAL outcome et al., 2012 [4]; Dal vessel et al., 2012 [6]; Stein et al., 2010 [12]; Accelerate AM et al., 2017 [1]. The values of each study (represented by black diamonds), in which the size is determined by 95% CI; the effect size of each individual study in the meta-analysis (represented by blue squares).



Supplementary Figure S5. Forest Plot of the Outcome of Revascularization

Ballantyne* et al., 2017 Am J Cardiol Vol. 120 [2]; DEFINE CP et al., 2010 [7]; E. Sammons et al., 2022 [8]; REALIZE JJ et al., 2015 [10]; Teramoto et al., 2017 [13]; DAL outcome et al., 2012 [4]; Dal vessel et al., 2012 [6]; Stein et al., 2010 [12]; Accelerate AM et al., 2017 [1]. The values of each study (represented by black diamonds), in which the size is determined by 95% CI; the effect size of each individual study in the meta-analysis (represented by blue squares).

References

[1]A. M. Lincoff, S. J. Nicholls, J. S. Riesmeyer, P. J. Barter, H. B. Brewer, K. A. A. Fox, C. M. Gibson, C. Granger, V. Menon, G. Montalescot, D. Rader, A. R. Tall, E. McErlean, K. Wolski, G. Ruotolo, B. Vangerow, G. Weerakkody, S. G. Goodman, D. Conde, D. K. McGuire, J. C. Nicolau, J. L. Leiva-Pons, Y. Pesant, W. Li, D. Kandath, S. Kouz, N. Tahirkheli, D. Mason, S. E. Nissen, and ACCELERATE Investigators, "Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease," *N. Engl. J. Med.*, vol. 376, no. 20, pp. 1933–1942, May 2017.

[2]C. M. Ballantyne, S. Shah, A. Sapre, T. B. Ashraf, S. C. Tobias, T. Sahin, P. Ye, Y. Dong, W. H.-H. Sheu, D.-H. Kang, P. R. Ferreira Rossi, Y. Moiseeva, I. R. Briones, A. O. Johnson-Levonas, and Y. B. Mitchel, "A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol," *Am. J. Cardiol.*, vol. 120, no. 4, pp. 569–576, Aug. 2017.

[3]C. M. Ballantyne, S. Shah, U. Kher, J. A. Hunter, G. G. Gill, M. D. Cressman, T. B. Ashraf, A. O. Johnson-Levonas, and Y. B. Mitchel, "Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol," *Am. J. Cardiol.*, vol. 119, no. 3, pp. 388–396, Feb. 2017.

[4]G. G. Schwartz, A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, E. Leitersdorf, J. J. V. McMurray, H. Mundl, S. J. Nicholls, P. K. Shah, J.-C. Tardif, R. S. Wright, and dal-OUTCOMES Investigators, "Effects of dalcetrapib in patients with a recent acute coronary syndrome," *N. Engl. J. Med.*, vol. 367, no. 22, pp. 2089–2099, Nov. 2012.

[5]Z. A. Fayad, V. Mani, M. Woodward, D. Kallend, M. Abt, T. Burgess, V. Fuster, C. M. Ballantyne, E. A. Stein, J.-C. Tardif, J. H. F. Rudd, M. E. Farkouh, A. Tawakol, and dal-PLAQUE Investigators, "Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial," *Lancet Lond. Engl.*, vol. 378, no. 9802, pp. 1547–1559, Oct. 2011.

[6]T. F. Lüscher, S. Taddei, J.-C. Kaski, J. W. Jukema, D. Kallend, T. Münzel, J. J. P. Kastelein, J. E. Deanfield, and dal-VESSEL Investigators, "Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial," *Eur. Heart J.*, vol. 33, no. 7, pp. 857–865, Apr. 2012.

[7]C. P. Cannon, S. Shah, H. M. Dansky, M. Davidson, E. A. Brinton, A. M. Gotto, M. Stepanavage, S. X. Liu, P. Gibbons, T. B. Ashraf, J. Zafarino, Y. Mitchel, and P. Barter, "Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease," *N. Engl. J. Med.*, vol. 363, no. 25, pp. 2406–2415, Dec. 2010.

[8]The HPS3/TIMI55-REVEAL Collaborative Group, Writing Committee, E. Sammons, J. C. Hopewell, F. Chen, W. Stevens, K. Wallendszus, E. Valdes-Marquez, R. Dayanandan, C. Knott, K. Murphy, E. Wincott, A. Baxter, R. Goodenough, M. Lay, M. Hill, S. Macdonnell, G. Fabbri, D. Lucci, M. Fajardo-Moser, S. Brenner, D. Hao, H. Zhang, J. Liu, B. Wuhan, S. Mosegaard, W. Herrington, C. Wanner, C. Angermann, G. Ertl, A. Maggioni, P. Barter, B. Mihaylova, Y. Mitchel, R. Blaustein, S. Goto, J. Tobert, P. DeLucca, Y. Chen, Z. Chen, A. Gray, R. Haynes, J. Armitage, C. Baigent, S. Wiviott, C. Cannon, E. Braunwald, R. Collins, L. Bowman, M. Landray, and REVEAL Collaborative Group, "Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease," *Eur. Heart J.*, vol. 43, no. 14, pp. 1416–1424, Apr. 2022.

[9]V. Menon, A. Kumar, D. R. Patel, J. St John, J. Riesmeyer, G. Weerakkody, G. Ruotolo, K. E. Wolski, E. McErlean, P. C. Cremer, S. J. Nicholls, A. M. Lincoff, and S. E. Nissen, "Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial," *Bmj Open Diabetes Res. Care*, vol. 8, no. 1, p. e000943, Mar. 2020.
[10]J. J. P. Kastelein, J. Besseling, S. Shah, J. Bergeron, G. Langslet, G. K. Hovingh, N. Al-Saady, M. Koeijvoets, J. Hunter, A. O. Johnson-Levonas, J. Fable, A. Sapre, and Y. Mitchel, "Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study," *Lancet Lond. Engl.*, vol. 385, no. 9983, pp. 2153–2161, May 2015.
[11]HPS3/TIMI55–REVEAL Collaborative Group, L. Bowman, J. C. Hopewell, F. Chen, K. Wallendszus, W. Stevens, R. Collins, S. D. Wiviott, C. P. Cannon, E. Braunwald, E. Sammons, and M. J. Landray, "Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease," *N. Engl. J. Med.*, vol. 377, no. 13, pp. 1217–1227, Sep. 2017.
[12]E. A. Stein, E. S. G. Stroes, G. Steiner, B. M. Buckley, A. M. Capponi, T. Burgess, E. J. Niesor, D. Kallend, and J. J. P. Kastelein, "Safety and tolerability of dalcetrapib," *Am. J. Cardiol.*, vol. 104, no. 1, pp. 82–91, Jul. 2009.
[13]T. Teramoto, H. Daida, K. Ikewaki, H. Arai, Y. Maeda, M. Nakagomi, M. Shirakawa, Y. Watanabe, T. Kakikawa, H. Numaguchi, A. O. Johnson-Levonas, and R. O. Blaustein, "Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia," *Atherosclerosis*, vol. 261, pp. 69–77, Jun. 2017.